Bile Duct Cancer Market 2018-2023 Ongoing Trend | Growing at Remarkable CAGR of 9.2% with Pfizer Inc., F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company

Market Research Future with their unique quality of simplifying the market research study, announces a deep study report on “Bile Duct Cancer Market Research Report – Global Forecast Till 2023” Gives industry size, top players and worldwide demand

Market Scenario:

Bile duct cancer or cholangiocarcinoma is a form of cancer in which epithelial cells are mutated, i.e., they show epithelial differentiation in the bile duct. It is a type of rare neoplasm. According to the National Cancer Institute, in 2014, there were an estimated 66,771 people living with liver and intrahepatic bile duct cancer in the United States. Moreover, the disease is expected to cause 28,920 deaths by the end of 2017 accounting for 4.8% of all cancer deaths. Rates for new liver and intrahepatic bile duct cancer cases have risen by an average 2.7% each year over the last 10 years. Death rates have been estimated to have risen by an average of 2.6% each year over 2005-2014. Such an increase in the prevalence of bile duct cancer has boosted the market. Additionally, rising healthcare expenditures, increasing awareness for the disease and investments in the R&D for treatment procedures is fuelling the market further. However, high cost of treatment and related side effects along with low healthcare expenditures in the developing economies is expected to restrain the market during the forecasted period.

The global bile duct cancer market is expected to grow at an approximate CAGR of 9.2% during the forecast period.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/4741

Segmentation

The global bile duct cancer market is segmented on the basis of types, diagnosis, treatment, and end users.

On the basis of types, the market is segmented into intrahepatic, extrahepatic, and others.

On the basis of diagnosis, the market is segmented into blood tests, abdominal imaging, surgery, and others. The diagnosis segment by abdominal imaging is sub segmented into endoscopic retrograde cholangiopancreatography (ERCP), percutaneous transhepatic cholangiography (PTC), magnetic resonance cholangiopancreatography (MRCP), and others.

On the basis of treatment, the market is segmented into chemotherapy, radiotherapy, and others. The chemotherapy segment is sub segmented into 5-fluorouracil, gemcitabine, cisplatin, and others.

On the basis of end users, the market is segmented into hospital &clinics, academic institutes, research organizations and others.

Regional Analysis

The Americas dominates the global bile duct cancer market owing to a well-developed healthcare sector. Apart from this, increasing number of patients, increasing healthcare expenditure have boosted the growth of the market in the Americas. According to the Centers for Disease Control and Prevention, U.S. health care spending in 2015, reached $3.2 trillion or $9,990 per person which accounted for 17.8% of the total GDP.

Europe is the second largest bile duct cancer market, which is followed by Asia Pacific. Availability of funds for research, huge patient population and government support for research & development drives the European market.

Asia Pacific is the fastest growing region for the market due to the presence of a huge patient population, continuously developing economies like India and China, and presence of huge opportunity in the market. According to Indian Brand Equity Fund, the per capita healthcare expenditure in India is estimated to grow at a CAGR of 5% during 2008-15 and reach USD 68.6 by 2015.

On the other hand, the Middle East & Africa has the least share in the global bile duct cancer market due to the presence of poor economy especially in Africa region. Majority of the market of this region is held by the Middle East due to a well-developed healthcare sector and huge healthcare expenditure.

Key players for global bile duct cancer market

The key players for the global bile duct cancer market are Pfizer Inc. (U.S.), F. Hoffmann-La Roche Ltd (Europe), Bristol-Myers Squibb Company (U.S.), Teva Pharmaceutical Industries Ltd. (Middle East), Eli Lilly and Company. (U.S.), Sanofi (Europe), Fresenius Kabi AG (Europe), Mylan N.V. (U.S.), and others.

Apply for Exclusive Discount @ https://www.marketresearchfuture.com/check-discount/4741

Detailed Table of Contents:

1 Report Prologue

2 Market Introduction

2.1 Definition

2.2 Scope Of The Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

3 Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

4 Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

… Continued!



Send An Enquiry @ https://www.marketresearchfuture.com/enquiry/4741

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

This release was published on openPR.